According to FDA guidance, GLP-1 medications are not recommended for people who have: Pregnancy, because safety data are limited and pregnancy requires appropriate weight gain and nutrient storage A prior history of pancreatitis, due to a risk of triggering inflammation of the pancreas A history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2), a rare genetic condition linked to thyroid cancer in animal studies A clinician will review your medical history carefully to determine whether these medications are appropriate for you
These findings have expanded how doctors think about using these medications
The field of GLP-1 medications continues to evolve rapidly
In some of the trials, we saw that individuals who had those variants were unable to lower their blood glucose levels as effectively after six months of treatment, said Anna Gloyn, DPhil, professor of pediatrics and of genetics, and one of the studys senior authors
Schwarz says the commentary is a call for disciplined use, not a warning against the class of medications
This is especially important considering the increasing use of these medications. The authors write that, to their knowledge, this is the first case detailing a patient developing this serious condition after starting tirzepatide for diabetes (in contrast to those treated with tirzepatide for weight loss)
